GlassScriptPhysician profile
Leslie A Clark
NPI 1700482163
$1,826.18
in general payments reported to CMS, 2019-2025
27 companies · $33.03 in 2025
The $33.03 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $614 · 2022: $228 · 2023: $592 · 2024: $359 · 2025: $33.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $364.51 | 2021-2022 | |
| Abbvie INC. | $247.41 | 2023-2024 | |
| Astellas Pharma US INC | $148.47 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.38 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $121.67 | 2021 | |
| Amgen INC. | $100.33 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $78.96 | 2021-2024 | Wegovy, Rybelsus |
| Millicent US INC | $71.91 | 2022-2025 | Intrarosa, Femring |
| Medicomp INC | $56.81 | 2023 | Telepatch Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $54.08 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Edwards Lifesciences Corporation | $48.89 | 2021 | |
| Lilly USA, LLC | $48.07 | 2023 | Jardiance, Emgality, Trulicity |
| Janssen Pharmaceuticals, INC | $41.29 | 2021 | |
| Insulet Corporation | $40.98 | 2022-2023 | Omnipod |
| Daiichi Sankyo INC. | $40.18 | 2023-2024 | Injectafer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.21 | 2023 | |
| Esperion Therapeutics, INC. | $23.69 | 2021 | |
| Medtronic, INC. | $23.03 | 2024 | Intellis Adaptivestim |
| Impulse Dynamics (USA) INC. | $19.45 | 2021 | |
| Sumitomo Pharma America, INC. | $18.43 | 2023 | Gemtesa |
| Dexcom, INC. | $18.12 | 2023 | Dexcom G6 Transmitter |
| Nevro Corp. | $17.34 | 2024 | Senza |
| Revance Therapeutics, INC. | $15.14 | 2025 | Daxxify |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Amarin Pharma, INC. | $13.80 | 2021 | |
| Exact Sciences Corporation | $13.20 | 2023 | Cologuard Collection Kit |
| Corium, LLC | $6.83 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.